ABEO

2.4201.22%
VS

Vishwas Seshadri

President, CEO & Director

Dr. Vishwas Seshadri, also known as Vish, Ph.D. & M.B.A., serves as Chief Executive Officer, President and Director at Abeona Therapeutics Inc. since October 15, 2021. He served as the Senior Vice President and the Head of Research and Clinical Development at Abeona Therapeutics Inc. since June 01, 2021 until October 15, 2021. He has an experience in academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell therapies. Dr. Seshadri had been with the Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS). At Celgene (BMS), Dr. Seshadri served in roles of increasing responsibility focused on research & development and commercialization for novel therapies in hematology and oncology, most recently as an Executive Director & Worldwide Brand Leader for Breyanzi® (lisocabtagene maraleucel; liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. While at Celgene, he led franchise level marketing and the project management office for CAR T commercialization and led teams supporting the successful global launch of Breyanzi®. He also led development project teams for clinical development and regulatory submissions for REVLIMID® (lenalidomide) in lymphoma, strategic go/no-go decisions for Avadomide and IMFINZI® (durvalumab) while implementing program-wide efficiency measures, and managed post-marketing commitments for ISTODAX® (romidepsin). Previously, he was the Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories, where he led cell-line development, current Good Manufacturing Practices (cGMP) cell banking, characterization, and cell culture optimization for biosimilars. Dr. Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology and his post-doc in epigenetics at University of Arizona and earned his M.B.A. in Finance and Healthcare from the Wharton School of the University of Pennsylvania.

公司职务